|Congress Continues to Question DQSA Implementation|
Congress Continues to Question DQSA Implementation
As part of this year’s Compounders on Capitol Hill, attendees visited House offices asking for support of a letter from Congressman Bilirakis (R-FL) to the Food and Drug Administration (FDA) that raised questions about the agency’s interpretation and implementation of the Drug Quality & Security Act.
In addition to concerns about how the FDA views office-use dispensing
in those states that permit it, repackaging of medications, the impact
on patient access, and the promotion of 503B outsourcing facilities
before the agency has completed the promulgation of regulations,
Congressman Bilirakis and others signing onto the letter are
specifically querying why the FDA appears to be ignoring specific
Congressional intent. More and more House members are signing onto the
letter and IACP expects it to be forwarded on to the FDA by the end of
June. To see a copy of the Bilirakis letter, please click here. To view the IACP “Ask” document explaining it, click here.
1/20/2017 » 1/22/2017
The Science of Pharmaceutical Compounding: Non-Sterile Training
1/21/2017 » 1/22/2017
Essential Elements of Prescription Hormone Compounding
Tell us how compounded pharmaceuticals have helped you, someone you know, or how you have helped someone as a practicing compounding pharmacist. Help us protect your continued access to pharmacy compounding!
Share the P3 community and the value and necessity of personalized prescriptions with your friends.